(Source: Business Wire)
Ceragenix Pharmaceuticals, Inc.("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with Megapharm Ltd., an Israeli company, ("Megapharm"), to commercialize EpiCeram®, a topical cream for treating atopic dermatitis and other dry skin conditions in Israel and the Palestinian territories (the "Territory"). The Agreement grants Megapharm exclusivity in the Territory for the distribution and marketing of EpiCeram® while Ceragenix will be responsible for the manufacturing and supply of the product. Megapharm is also responsible for obtaining regulatory clearance to market EpiCeram® in the Territory. Financial terms were not disclosed.
Steven Porter Chairman and Chief Executive Officer of Ceragenix said, "We are pleased to expand our international distribution network for EpiCeram® by entering into this agreement with a well respected company such as Megapharm."
Miron Drucker, CEO of Megapharm, said "We are delighted to have forged an agreement with Ceragenix to market EpiCeram Cream in Israel. We have been active in dermatology for many years and this is an important step in the company's strategy to strengthen our presence and expand our portfolio in the dermatology field".
About EpiCeram®
EpiCeram® is a topical cream that utilizes Ceragenix's Barrier Repair Technology. In April 2006, the FDA provided clearance to market EpiCeram® to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis (eczema), irritant contact dermatitis, radiation dermatitis, and other dry skin conditions by maintaining a moist wound and skin environment. All of these conditions are associated with a deficient skin barrier function.
About Ceragenix
Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; Ceragenins for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. All Ceragenin and Cerashield products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr.
